vs
Consensus Cloud Solutions, Inc.（CCSI）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Consensus Cloud Solutions, Inc.的季度营收约是MESA LABORATORIES INC的1.4倍（$88.5M vs $65.1M），Consensus Cloud Solutions, Inc.净利率更高（27.9% vs 5.6%，领先22.3%），MESA LABORATORIES INC同比增速更快（3.6% vs 1.5%），Consensus Cloud Solutions, Inc.自由现金流更多（$38.5M vs $18.0M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 0.6%）
Consensus Cloud Solutions是一家云解决方案提供商，核心产品包括加密数字传真、安全文档交换、工作流程自动化工具，主要面向医疗、法律、金融服务等领域的北美企业客户提供相关服务。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
CCSI vs MLAB — 直观对比
营收规模更大
CCSI
是对方的1.4倍
$65.1M
营收增速更快
MLAB
高出2.1%
1.5%
净利率更高
CCSI
高出22.3%
5.6%
自由现金流更多
CCSI
多$20.4M
$18.0M
两年增速更快
MLAB
近两年复合增速
0.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $88.5M | $65.1M |
| 净利润 | $24.7M | $3.6M |
| 毛利率 | 80.9% | 64.2% |
| 营业利润率 | 42.7% | 12.2% |
| 净利率 | 27.9% | 5.6% |
| 营收同比 | 1.5% | 3.6% |
| 净利润同比 | 16.7% | 316.6% |
| 每股收益（稀释后） | $1.30 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCSIMLAB
| Q1 26 | $88.5M | — | ||
| Q4 25 | $87.1M | $65.1M | ||
| Q3 25 | $87.8M | $60.7M | ||
| Q2 25 | $87.7M | $59.5M | ||
| Q1 25 | $87.1M | $62.1M | ||
| Q4 24 | $87.0M | $62.8M | ||
| Q3 24 | $87.8M | $57.8M | ||
| Q2 24 | $87.5M | $58.2M |
净利润CCSIMLAB
| Q1 26 | $24.7M | — | ||
| Q4 25 | $20.5M | $3.6M | ||
| Q3 25 | $22.1M | $2.5M | ||
| Q2 25 | $20.8M | $4.7M | ||
| Q1 25 | $21.2M | $-7.1M | ||
| Q4 24 | $18.1M | $-1.7M | ||
| Q3 24 | $21.1M | $3.4M | ||
| Q2 24 | $23.9M | $3.4M |
毛利率CCSIMLAB
| Q1 26 | 80.9% | — | ||
| Q4 25 | 80.0% | 64.2% | ||
| Q3 25 | 80.0% | 61.5% | ||
| Q2 25 | 79.9% | 62.0% | ||
| Q1 25 | 79.3% | 61.8% | ||
| Q4 24 | 79.5% | 63.3% | ||
| Q3 24 | 79.9% | 61.3% | ||
| Q2 24 | 80.4% | 64.0% |
营业利润率CCSIMLAB
| Q1 26 | 42.7% | — | ||
| Q4 25 | 41.1% | 12.2% | ||
| Q3 25 | 43.2% | 7.8% | ||
| Q2 25 | 44.5% | 5.1% | ||
| Q1 25 | 43.0% | 2.4% | ||
| Q4 24 | 38.4% | 9.2% | ||
| Q3 24 | 43.8% | 6.1% | ||
| Q2 24 | 45.6% | 9.6% |
净利率CCSIMLAB
| Q1 26 | 27.9% | — | ||
| Q4 25 | 23.5% | 5.6% | ||
| Q3 25 | 25.2% | 4.1% | ||
| Q2 25 | 23.7% | 8.0% | ||
| Q1 25 | 24.3% | -11.4% | ||
| Q4 24 | 20.8% | -2.7% | ||
| Q3 24 | 24.1% | 5.9% | ||
| Q2 24 | 27.3% | 5.8% |
每股收益（稀释后）CCSIMLAB
| Q1 26 | $1.30 | — | ||
| Q4 25 | $1.06 | $0.65 | ||
| Q3 25 | $1.15 | $0.45 | ||
| Q2 25 | $1.07 | $0.85 | ||
| Q1 25 | $1.07 | $-1.30 | ||
| Q4 24 | $0.92 | $-0.31 | ||
| Q3 24 | $1.09 | $0.63 | ||
| Q2 24 | $1.24 | $0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $92.3M | $29.0M |
| 总债务越低越好 | $556.8M | $68.4M |
| 股东权益账面价值 | $22.0M | $186.7M |
| 总资产 | $678.7M | $434.8M |
| 负债/权益比越低杠杆越低 | 25.31× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资CCSIMLAB
| Q1 26 | $92.3M | — | ||
| Q4 25 | $74.7M | $29.0M | ||
| Q3 25 | $97.6M | $20.4M | ||
| Q2 25 | $57.9M | $21.3M | ||
| Q1 25 | $53.4M | $27.3M | ||
| Q4 24 | $33.5M | $27.3M | ||
| Q3 24 | $54.6M | $24.3M | ||
| Q2 24 | $49.2M | $28.5M |
总债务CCSIMLAB
| Q1 26 | $556.8M | — | ||
| Q4 25 | $558.4M | $68.4M | ||
| Q3 25 | $578.6M | $69.4M | ||
| Q2 25 | $578.2M | $70.3M | ||
| Q1 25 | $583.7M | $71.3M | ||
| Q4 24 | $593.0M | $72.2M | ||
| Q3 24 | $612.5M | $73.1M | ||
| Q2 24 | $642.8M | $74.1M |
股东权益CCSIMLAB
| Q1 26 | $22.0M | — | ||
| Q4 25 | $13.8M | $186.7M | ||
| Q3 25 | $-2.6M | $178.5M | ||
| Q2 25 | $-26.5M | $172.5M | ||
| Q1 25 | $-49.4M | $159.8M | ||
| Q4 24 | $-79.5M | $155.2M | ||
| Q3 24 | $-93.2M | $161.5M | ||
| Q2 24 | $-124.4M | $150.7M |
总资产CCSIMLAB
| Q1 26 | $678.7M | — | ||
| Q4 25 | $663.8M | $434.8M | ||
| Q3 25 | $675.0M | $430.4M | ||
| Q2 25 | $641.5M | $435.7M | ||
| Q1 25 | $629.6M | $433.3M | ||
| Q4 24 | $602.2M | $433.3M | ||
| Q3 24 | $622.5M | $454.1M | ||
| Q2 24 | $608.5M | $440.4M |
负债/权益比CCSIMLAB
| Q1 26 | 25.31× | — | ||
| Q4 25 | 40.54× | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.8M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $38.5M | $18.0M |
| 自由现金流率自由现金流/营收 | 43.5% | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 1.86× | 5.17× |
| 过去12个月自由现金流最近4个季度 | $110.6M | $37.9M |
8季度趋势，按日历期对齐
经营现金流CCSIMLAB
| Q1 26 | $45.8M | — | ||
| Q4 25 | $15.2M | $18.8M | ||
| Q3 25 | $51.6M | $8.2M | ||
| Q2 25 | $28.3M | $1.9M | ||
| Q1 25 | $40.9M | $12.7M | ||
| Q4 24 | $11.1M | $18.1M | ||
| Q3 24 | $41.6M | $5.3M | ||
| Q2 24 | $24.4M | $10.7M |
自由现金流CCSIMLAB
| Q1 26 | $38.5M | — | ||
| Q4 25 | $7.3M | $18.0M | ||
| Q3 25 | $44.4M | $7.1M | ||
| Q2 25 | $20.3M | $884.0K | ||
| Q1 25 | $33.7M | $11.9M | ||
| Q4 24 | $3.1M | $17.3M | ||
| Q3 24 | $33.6M | $3.5M | ||
| Q2 24 | $15.8M | $9.9M |
自由现金流率CCSIMLAB
| Q1 26 | 43.5% | — | ||
| Q4 25 | 8.4% | 27.7% | ||
| Q3 25 | 50.6% | 11.7% | ||
| Q2 25 | 23.2% | 1.5% | ||
| Q1 25 | 38.7% | 19.2% | ||
| Q4 24 | 3.6% | 27.6% | ||
| Q3 24 | 38.3% | 6.0% | ||
| Q2 24 | 18.1% | 16.9% |
资本支出强度CCSIMLAB
| Q1 26 | — | — | ||
| Q4 25 | 9.1% | 1.1% | ||
| Q3 25 | 8.2% | 1.8% | ||
| Q2 25 | 9.1% | 1.7% | ||
| Q1 25 | 8.3% | 1.2% | ||
| Q4 24 | 9.2% | 1.3% | ||
| Q3 24 | 9.1% | 3.1% | ||
| Q2 24 | 9.8% | 1.5% |
现金转化率CCSIMLAB
| Q1 26 | 1.86× | — | ||
| Q4 25 | 0.74× | 5.17× | ||
| Q3 25 | 2.34× | 3.32× | ||
| Q2 25 | 1.36× | 0.40× | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 1.97× | 1.54× | ||
| Q2 24 | 1.02× | 3.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCSI
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
